Empagliflozin/Linagliptin/Metformin

恩格列净/利格列汀/二甲双胍

Report date: 2026/03/23 20:03:44

Base Information

Drug NameEmpagliflozin/Linagliptin/Metformin
Drug Alias Name恩格列净+二甲双胍+利格列汀Empagliflozin/Metformin/Linagliptin利格列汀/恩格列净/盐酸二甲双胍Empagliflozin+Metformin+LinagliptinLinagliptin/Empagliflozin/Metformin Hydrochloride +[12] 
ClassificationSmall molecules
Mechanisms of ActionProtein kinase AMP-activated non-catalytic subunit beta 1 activatorsDipeptidyl peptidase IV inhibitorsSodium/glucose cotransporter 2 inhibitors
TargetsDipeptidyl peptidase IVProtein kinase AMP-activated non-catalytic subunit beta 1Sodium/glucose cotransporter 2
Therapy Area/IndicationsDiabetes Mellitus, Type 2
Global Approved IndicationsDiabetes Mellitus, Type 2
Approved Indications in ChinaN/A
Original Approved Country/TerritoryUnited States
Original Approved Date2020/01/27
Country/TerritoryUnited StatesGermanyJordan
CombinationsYes LinagliptinMetformin HydrochlorideEmpagliflozin
Global Highest StatusApproved
Highest Status in ChinaN/A
Originator CompaniesBoehringer Ingelheim International GmbhEli Lilly And Company
China Registration ClassN/A

Develop Information

Active CompaniesHumanis Saglık Anonim SirketiBoehringer Ingelheim International Gmbh
Inactive CompaniesC.H. Boehringer Sohn Ag & Co. KgEli Lilly And Company
Active IndicationsDiabetes Mellitus, Type 2
Inactive IndicationsN/A

Other Information

ATC CodeA10BD
Related LinksN/A